Background: Endoscopic mucosal resection (EMR) is increasingly being used as a first-line treatment for Barrett esophagus (BE) with high-grade dysplasia (HGD) and intramucosal adenocarcinoma (IMC). We reviewed our experience with endoscopic treatment of BE with HGD and IMC at our institution with respect to eradication rates, complications and long-term recurrence.
T he incidence of esophageal adenocarcinoma is increasing 2% per year. 1 The most clinically important risk factor for the development of esophageal adenocarcinoma is Barrett esophagus (BE), a premalignant change from normal esophageal squamous epithelium to metaplastic columnar epithelium-containing goblet cells resulting from gastroesophageal reflux. 2 Endoscopic surveillance of BE is the standard of care to identify development of dysplasia. The development of dysplasia further enhances the risk of progression to adenocarcinoma.
The management of BE with high-grade dysplasia (HGD) is controversial. Multiple guidelines exist with respect to the management of HGD. 3, 4 Traditionally, the main options were endoscopic surveillance or eradication of HGD through surgical resection of the esophagus. There has been some controversy about the risk of progression of HGD to adenocarcinoma during surveillance. Some studies have reported a relatively high risk of progression, 5 whereas other larger studies have argued that "low-risk" HGD lesions can be safely managed with endoscopic surveillance. 6, 7 Conversely, the surgical option, an esophagectomy, remains a complex and morbid operation. 8 Novel targeted endoscopic techniques, such as endoscopic mucosal resection (EMR) and radiofrequency ablation, are associated with lower morbidity and should be considered. 3 Complete eradication of dysplasia can be achieved with these techniques in up to 96% of patients. [9] [10] [11] [12] We previously argued that a balanced approach should be taken: selected patients with HGD can be followed closely with endoscopic surveillance and EMR of any nodular lesions, followed by radiofrequency ablation for long segments as required. 13 At our centre, thoracic surgery and surgical endoscopists work collaboratively to select appropriate patients for endoscopic eradication therapy.
Endoscopic mucosal resection can also be used to diagnose and treat selected patients with intramucosal adenocarcinoma (IMC) and is now considered first-line therapy for discrete unifocal IMC.
14 As a resection technique, EMR yields a pathology specimen that can be used to diagnose local submucosal invasion. In the absence of invasion, IMC can be adequately treated with EMR and continued regular surveillance endoscopy. Successful curative resection rates of IMC with EMR have been in the range of 57%-96%. 15, 16 In the present study, we sought to review our experience with endoscopic treatment of BE with HGD and IMC at our institution with respect to eradication rates, complications and long-term recurrence.
Methods
Patients were identified from a pre-established prospectively collected endoscopic procedures database (Clinical Outcomes Research Initiative [CORI]). We obtained research ethics board approval. We performed a search using "esophagogastroduodenoscopy" as procedure in conjunction with the keywords "Barrett's esophagus" and "malignancy." Results were then manually searched to identify patients who underwent EMR between October 2010 and August 2014. Follow-up data were retrospectively collected from electronic records for endoscopy, imaging, operative and pathology reports; ambulatory clinic reports; and the last documented hospital visit.
The EMR procedure was performed using the Duette Multi-Band Mucosectomy device (Cook Medical). Dysplastic lesions were identified with a combination of location of prior biopsy sites, mucosal and vascular pattern abnormalities, and narrow band imaging. We used a capfitted endoscope to aspirate and band the selected mucosal area, followed by a snare resection supplemented with electrocautery according to the manufacturer's instructions. We used this technique to resect all lesions that appeared dysplastic, either as a single specimen or in a piecemeal fashion to achieve complete gross resection.
We then reviewed pathology specimen results, and follow-up was determined depending on the findings. In the presence of invasive adenocarcinoma, the patient was referred for consideration of esophagectomy. In marginnegative IMC and HGD, patients were followed with endoscopy at 3-month intervals with repeat EMR of any suspicious lesions until there was eradication of all dysplastic mucosa, followed by an endoscopic surveillance regimen with 4-quadrant biopsies. In the presence of persistent long-segment BE, radiofrequency ablation was performed with a BarrX catheter after resection of discrete lesions amenable to EMR.
Results
We identified 28 consecutive patients undergoing EMR. Sixteen patients were referred with BE with dysplasia, and 12 were referred with IMC. Five of the patients referred for BE with dysplasia were eventually referred for radiofrequency ablation. Twenty patients were men and 8 were women. The mean age of patients was 67 (range 49-86) years. The median duration of follow-up was 371 days. A summary of patient results is shown in Figure 1 .
Barrett esophagus with dysplasia
Of the 28 patients with BE referred for EMR, 14 patients had HGD, 1 patient had low-grade dysplasia (LGD), and 1 had intermediate dysplasia. Of those, 11 patients had biopsy-proven complete eradication of dysplasia. These results were achieved after a median of 1 (range 1-2) EMR session; the patients were followed for a median of 175 days and underwent a median of 3 endoscopy sessions, including the initial EMR sessions.
At final follow-up, 6 of these 11 patients had normal squamous epithelium on biopsy. These patients were followed for a median of 193 days, receiving a median of 1 (range 1-2) EMR session and 3.5 (range 2-5) total endoscopy sessions. Three of these patients were referred for radiofrequency ablation, as they had long-segment BE.
At follow-up, 5 of these 11 patients had BE with no evidence of dysplasia on random biopsy. However, this patient subgroup has the shortest follow-up at a median of 121 days, receiving a median 2 (range 1-2) EMR sessions and 2 (range 2-4) total endoscopy sessions. Their follow-up is ongoing, with the intention of complete eradication of BE.
Three patients referred for EMR management of HGD did not achieve eradication of dysplasia. One patient died of unrelated acute lymphoblastic leukemia after a single EMR session. One patient had a single EMR session revealing HGD, and then surveillance endoscopy revealing BE without dysplasia followed by LGD on the last 2 sessions. In spite of persistent LGD on biopsy, this patient has been followed with close endoscopic surveillance for almost 4 years, and there has been no recurrent nodular disease. One patient has been followed with serial endoscopy and EMR over a period of 1.6 years, having received 4 EMR sessions and 2 surveillance endoscopy sessions during this time. Unfortunately, this patient has had persistent biopsies showing HGD. This patient had severe refractory reflux and, in the interim of endoscopic followup, underwent antireflux surgery. At the last surveillance endoscopy, pathological review confirmed BE with HGD, but the disease was limited to a discrete unifocal area. Endoscopic surveillance continues, with consideration of radiofrequency ablation.
Intramucosal adenocarcinoma
Twelve patients referred for EMR management had IMC. Three of these patients were referred for consideration of esophagectomy after a single EMR session, based on pathology results compatible with invasive disease. One One patient was eventually found to have invasive adenocarcinoma on EMR specimen after 6 endoscopy sessions spread over a period of 1.3 years. Initial EMR pathology was IMC. Subsequent EMR specimens showed HGD. The sixth EMR session showed invasive adenocarcinoma, and the patient was referred for esophagectomy. Final pathology from their esophagectomy showed no evidence of invasive adenocarcinoma, but a background of HGD.
Eight of the 12 patients referred for IMC had complete R0 resections with no endoscopic evidence of recurrence after a median of 1 (range 1-3) EMR session. These patients were followed for a median of 4.5 endoscopy sessions over a median of 1.6 years of follow-up. Six of 8 patients had normal squamous esophageal mucosa on random biopsy at the last documented surveillance. Two patients had evidence of BE without dysplasia at the last biopsy. For both patients, routine surveillance endoscopy is ongoing.
Complications
There were no perforations, and no patients experienced postoperative bleeding requiring repeat intervention. Strictures developed in 2 patients, who had 2 and 3 EMR sessions for HGD, respectively. Both patients were treated successfully with a single balloon dilatation.
discussion
Results from our experience are consistent with those of other series of endoscopic management of HGD. In our cohort referred for HGD, 11 of 14 (79%) patients had complete eradication of dysplasia. Although 2 patients have persistent dysplasia, HGD and LGD, they have been followed over the course of 570 and 1170 days, respectively, with close endoscopic surveillance and have shown no evidence of disease progression.
For patients referred for IMC, we achieved complete eradication of neoplasia in 8 of 9 (91%) patients.
Four patients were referred for consideration of esophagectomy in a fashion that did not affect oncologic outcome. Three of these 4 patients were immediately referred based on endoscopic appearance of submucosal invasion and corresponding pathologic confirmation of invasive adenocarcinoma. These were appropriate, timely referrals, as the 2 patients who underwent esophagectomy had evidence of nodal disease; final pathology was T3N1 and T0N1. One of these 4 patients had a delayed diagnosis of invasive adenocarcinoma after 6 endoscopy sessions over 466 days; however, the carcinoma detected after this time was an early curable carcinoma in situ.
Patients selected for our endoscopic management program had discrete unifocal nodules amenable to complete endoscopic resection. However, they must adhere to rigorous endoscopic surveillance. Our experience adds to the evidence that close endoscopic follow-up will detect progression of disease in a timely fashion.
Endoscopic ultrasonography was not used as a screening tool for patients selected for endoscopic management. This is consistent with other studies documenting the limited accuracy of endoscopic ultrasonography in staging early IMC and HGD. 17, 18 Radiofrequency ablation was offered selectively to patients with long-segment BE after nodular regions were pathologically assessed by EMR. We chose to refer these patients for ablation, as serial EMR of long-segment BE has been associated with a higher rate of postoperative strictures, ranging from 37%-86%. 12, 19 A recent systematic review comparing serial EMR with EMR plus radiofrequency ablation for eradication of BE with HGD or IMC revealed similar rates of eradication of neoplasia (94.9% v. 93.4%, respectively) and metaplasia (79.6% v. 73.1%) at the expense of a significantly higher rate of structuring (33% v. 10%). 20 Esophageal varices are a potential comorbidity limiting the ability to safely perform EMR. Although our series did not capture this scenario, case reports have described preoperative transjugular intrahepatic portosystemic shunt to decrease portal pressure to diminish varices, allowing for EMR. An alternative approach is band ligation of nodular regions of HGD or IMC with biopsy as opposed to resection. The disadvantage of this technique is the lack is docu mentation of negative margin status. 21 
Limitations
Limitations of our study include the retrospective nature of the data, which limits our interpretation of the potential long-term results. Despite a median follow-up of more than a year, there was significant heterogeneity in the follow-up data, as a group of patients was still actively undergoing endoscopic therapy for BE. This limited number of patients may not capture rare but potentially important complications, such as post-EMR bleeding or delayed stricturing. Also, the candidate patient population must be motivated and able to adhere to strict follow-up, as complete resolution with EMR may take several sessions, depending on the extent of the BE.
conclusion
Endoscopic mucosal resection demonstrated safe management of this high-risk population of patients with BE with HGD and IMC. The lone patient in the IMC group who had a delayed diagnosis of invasive esophageal cancer actually turned out to have only in situ cancer.
Two patients in the HGD group have persistent dysplasia but have undergone close endoscopic surveillance for a long time period (570 and 1170 d, respectively) with no progression of disease. Complications were minor (stricture), and were readily treated with endoscopic therapy.
Our multidisciplinary experience supports that endoscopic management can be safely performed as first-line treatment for patients with BE with dysplastic changes and also for selected patients with IMC.
